Home> Products> Inhibitors> Tegobuvir-CAS 1000787-75-6
price inquiry for CAS:1000787-75-6, Product:Tegobuvir
For research use only. We do not sell to patients.

Tegobuvir CAS: 1000787-75-6

Category: Inhibitors
Product Name: Tegobuvir
Cat No: I000067
CAS No: 1000787-75-6
Synonyms: 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine
Molecular Formula: C25H14F7N5
Molecular Weight: 517.4
InChI: None
InChIKey: None
Solubility: 10 mM in DMSO
Target: HCV Protease
Storage: Store at -20°C
CAS 1000787-75-6,Tegobuvir
  • Description

Tegobuvir (GS-9190; GS 333126) is a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor.
IC50 Value:
Target: HCV
Tegobuvir is a novel imidazopyridine inhibitor of hepatitis C virus (HCV) RNA replication in vitro and has demonstrated potent antiviral activity in patients chronically infected with genotype 1 (GT1) HCV. Tegobuvir exhibits reduced activity against GT2a (JFH1) subgenomic replicons and GT2a (J6/JFH1) infectious virus, suggesting that the compd.'s mechanism of action involves a genotype-specific viral component.

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References

1:In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance. Vliegen I, Paeshuyse J, Zhong W, Neyts J.Antiviral Res. 2015 Aug;120:112-21. doi: 10.1016/j.antiviral.2015.05.011. Epub 2015 May 30. PMID: 26036224
2:All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Wyles DL, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS.Hepatology. 2014 Jul;60(1):56-64. doi: 10.1002/hep.27053. Epub 2014 May 28. PMID: 24501005
3:The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. Hebner CM, Han B, Brendza KM, Nash M, Sulfab M, Tian Y, Hung M, Fung W, Vivian RW, Trenkle J, Taylor J, Bjornson K, Bondy S, Liu X, Link J, Neyts J, Sakowicz R, Zhong W, Tang H, Schmitz U.PLoS One. 2012;7(6):e39163. doi: 10.1371/journal.pone.0039163. Epub 2012 Jun 13. PMID: 22720059 Free PMC Article
4:Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Wong KA, Xu S, Martin R, Miller MD, Mo H.Virology. 2012 Jul 20;429(1):57-62. doi: 10.1016/j.virol.2012.03.025. Epub 2012 Apr 28. PMID: 22543048 Free Article
5:The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR.Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744. PMID: 22006408
6:Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Pürstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W.Antimicrob Agents Chemother. 2011 Sep;55(9):4196-203. doi: 10.1128/AAC.00307-11. Epub 2011 Jul 11. PMID: 21746939 Free PMC Article

price inquiry for CAS:1000787-75-6, Product:Tegobuvir
Advanced Biomart